TetraLogic Pharmaceuticals Announces Selection Of Phase 2 Dose For Randomized Clinical Study Of Birinapant In Combination With Azacitidine In Naive Patients With Higher Risk Myelodysplastic Syndromes (MDS)

MALVERN, Pa., May 27, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that, based upon data from its Phase 1b study of birinapant in combination with azacitidine in patients with relapsed/refractory or naïve higher risk MDS, it selected a dose of 13mg/m2 twice weekly for three weeks out of four to be used in its Phase 2 clinical trial. The primary objective of the Phase 1b clinical study is to characterize the safety and tolerability and determine the recommended phase 2 dose of birinapant when administered in combination with azacitidine. Additional objectives of the study are to assess any preliminary indications of efficacy and pharmacodynamics of the combination.

Help employers find you! Check out all the jobs and post your resume.